The Epigenetic Basis of Diffuse Large B-Cell Lymphoma

Seminars in Hematology

Volumn 52, Issue 2, 2015, Pages 86-96

  Jiang, Yanwen ^a   Melnick, Ari ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; CYTOSINE; E1A ASSOCIATED P300 PROTEIN; HISTONE DEACETYLASE INHIBITOR; PROTEIN BCL 6; PROTEIN INHIBITOR; TRANSCRIPTION FACTOR EZH2;

B LYMPHOCYTE DIFFERENTIATION; BCL6 GENE; CANCER GENETICS; CREBBP GENE; DNA METHYLATION; ENHANCER REGION; EP300 GENE; EPIGENETICS; EZH2 GENE; GENE; GENE MUTATION; GERMINAL CENTER; HUMAN; KMT2D GENE; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SOMATIC MUTATION; ANIMAL; B LYMPHOCYTE; GENETIC EPIGENESIS; GENETICS; METABOLISM; MUTATION;

ANIMALS; B-LYMPHOCYTES; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION;

EID: 84925281562     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.01.003     Document Type: Review

References (74)

1. Chi P., Allis C.D., Wang G.G. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10:457-469.
2. Maze I., Noh K.M., Soshnev A.A., Allis C.D. Every amino acid matters: essential contributions of histone variants to mammalian development and disease. Nat Rev Genet 2014, 15:259-271.
3. Shen H., Laird P.W. Interplay between the cancer genome and epigenome. Cell 2013, 153:38-55.
4. Shaknovich R., Cerchietti L., Tsikitas L., et al. DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood 2011, 118:3559-3569.
5. Lai A.Y., Mav D., Shah R., et al. DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome Res 2013, 23:2030-2041.
6. De S., Shaknovich R., Riester M., et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet 2013, 9:e1003137.
7. Lai A.Y., Fatemi M., Dhasarathy A., et al. DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas. J Exper Med 2010, 207:1939-1950.
8. Bernstein B.E., Mikkelsen T.S., Xie X., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
9. Gan Q., Yoshida T., McDonald O.G., Owens G.K. Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. Stem Cells 2007, 25:2-9.
10. Beguelin W., Popovic R., Teater M., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23:677-692.
11. Heintzman N.D., Hon G.C., Hawkins R.D., et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009, 459:108-112.
12. Zhou V.W., Goren A., Bernstein B.E. Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 2011, 12:7-18.
13. Creyghton M.P., Cheng A.W., Welstead G.G., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 2010, 107:21931-21936.
14. Tan M., Luo H., Lee S., et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011, 146:1016-1028.
15. Hatzi K., Melnick A. Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trend Molec Med 2014, 20:343-352.
16. Velichutina I., Shaknovich R., Geng H., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010, 116:5247-5255.
17. Raaphorst F.M., van Kemenade F.J., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin[U+05F3]s disease. Am J Pathol 2000, 157:709-715.
18. Chase A., Cross N.C. Aberrations of EZH2 in cancer. Clin Cancer Res 2011, 17:2613-2618.
19. Caganova M., Carrisi C., Varano G., et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest 2013, 123:5009-5022.
20. Benetatos L., Voulgaris E., Vartholomatos G., Hatzimichael E. Non-coding RNAs and EZH2 interactions in cancer: long and short tales from the transcriptome. Int J Cancer 2013, 133:267-274.
21. Hatzi K., Jiang Y., Huang C., et al. A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep 2013, 4:578-588.
22. Beguelin W., Teater M., Hatzi K., et al. EZH2 and BCL6 cooperate to create the germinal center B-cell phenotype and induce lymphomas through formation and repression of bivalent chromatin domains. Blood 2013, 122(21):1.
23. Cerchietti L.C., Hatzi K., Caldas-Lopes E., et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest 2010, 120:4569-4582.
24. Polo J.M., Ci W., Licht J.D., Melnick A. Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood 2008, 112:644-651.
25. Morin R.D., Mendez-Lago M., Mungall A.J., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
26. Pasqualucci L., Trifonov V., Fabbri G., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011, 43:830-837.
27. Bodor C., Grossmann V., Popov N., et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood 2013, 122:3165-3168.
28. Okosun J., Bodor C., Wang J., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014, 46:176-181.
29. Jiang Y., Redmond D., Nie K., et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol 2014, 15:432.
30. Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42:181-185.
31. Sneeringer C.J., Scott M.P., Kuntz K.W., et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010, 107:20980-20985.
32. Yap D.B., Chu J., Berg T., et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117:2451-2459.
33. Berg T., Thoene S., Yap D., et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood 2014, 123:3914-3924.
34. Sahasrabuddhe A.A., Chen X., Chung F., Velusamy T., Lim M.S., Elenitoba-Johnson K.S. Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation. Oncogene 2015, 34:445-454.
35. Jin Q., Yu L.R., Wang L., et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 2011, 30:249-262.
36. Garbati M.R., Alco G., Gilmore T.D. Histone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8. Cancer Lett 2010, 291:237-245.
37. Pasqualucci L., Dominguez-Sola D., Chiarenza A., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
38. Herz H.M., Mohan M., Garruss A.S., et al. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Devel 2012, 26:2604-2620.
39. Lee J.E., Wang C., Xu S., et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. eLife 2013, 2:e01503.
40. Issaeva I., Zonis Y., Rozovskaia T., et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Molec Cell Biol 2007, 27:1889-1903.
41. Bogershausen N., Wollnik B. Unmasking Kabuki syndrome. Clinical Genet 2013, 83:201-211.
42. Lohr J.G., Stojanov P., Lawrence M.S., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012, 109:3879-3884.
43. Zhang J., Grubor V., Love C.L., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013, 110:1398-1403.
44. Guo C., Chen L.H., Huang Y., et al. KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation. Oncotarget 2013, 4:2144-2153.
45. Kim J.H., Sharma A., Dhar S.S., et al. UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. Cancer Res 2014, 74:1705-1717.
46. Kumar R., DiMenna L., Schrode N., et al. AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes. Nature 2013, 500:89-92.
47. Popp C., Dean W., Feng S., et al. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Nature 2010, 463:1101-1105.
48. Bhutani N., Brady J.J., Damian M., Sacco A., Corbel S.Y., Blau H.M. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature 2010, 463:1042-1047.
49. Morgan H.D., Dean W., Coker H.A., Reik W., Petersen-Mahrt S.K. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluripotent tissues: implications for epigenetic reprogramming. J Biol Chem 2004, 279:52353-52360.
50. Fritz E.L., Rosenberg B.R., Lay K., Mihailovic A., Tuschl T., Papavasiliou F.N. A comprehensive analysis of the effects of the deaminase AID on the transcriptome and methylome of activated B cells. Nat Immunol 2013, 14:749-755.
51. Dominguez M., Teater M., Chambwe N., et al. Demethylase activity of aid during germinal center B cell maturation could contribute to lymphomagenesis. Blood 2014, 124(21):59.
52. Shaknovich R., Geng H., Johnson N.A., et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010, 116:e81-e89.
53. Martin-Subero J.I., Kreuz M., Bibikova M., et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009, 113:2488-2497.
54. Jiang Y., Hatzi K., Shaknovich R. Mechanisms of epigenetic deregulation in lymphoid neoplasms. Blood 2013, 121:4271-4279.
55. Pan H., Jiang Y., Redmond D., et al. Epigenomic evolution in diffuse large B-cell lymphomas. Blood 2013, 122(21):634.
56. Chambwe N., Kormaksson M., Geng H., et al. Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood 2014, 123:1699-1708.
57. Kemp C.J., Moore J.M., Moser R., et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep 2014, 7:1020-1029.
58. McCabe M.T., Ott H.M., Ganji G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
59. Clozel T., Yang S., Elstrom R.L., et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013, 3:1002-1019.
60. Leshchenko V.V., Kuo P.Y., Jiang Z., Thirukonda V.K., Parekh S. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma. Clin Cancer REs 2014, 20:382-392.
61. Blum K.A., Liu Z., Lucas D.M., et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. Br J Haematol 2010, 150:189-195.
62. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012, 90:85-94.
63. Guo S.Q., Zhang Y.Z. Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma. Cancer Biol Med 2012, 9:85-89.
64. Cerchietti L., Leonard J.P. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology Am Soc Hematol Educ Program 2013, 2013:591-595.
65. Bjornsson H.T., Benjamin J.S., Zhang L., et al. Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome. Sci Transl Med 2014, 6:256ra135.
66. Garapaty-Rao S., Nasveschuk C., Gagnon A., et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol 2013, 20:1329-1339.
67. Knutson S.K., Wigle T.J., Warholic N.M., et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 2012, 8:890-896.
68. Konze K.D., Ma A., Li F., et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol 2013, 8:1324-1334.
69. Qi W., Chan H., Teng L., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012, 109:21360-21365.
70. Knutson S.K., Kawano S., Minoshima Y., et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Molec Cancer Ther 2014, 13:842-854.
71. Knutson S.K., Warholic N.M., Johnston L.D., et al. Synergistic anti-tumor activity of EZH2 inhibitors and glucocorticoid receptor agonists in models of germinal center non-Hodgkin lymphomas. PloS One 2014, 9:e111840.
72. Cerchietti L.C., Ghetu A.F., Zhu X., et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010, 17:400-411.
73. Cerchietti L.C., Yang S.N., Shaknovich R., et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 2009, 113:3397-3405.
74. Chapuy B., McKeown M.R., Lin C.Y., et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.